Another mafodotin-based ADC is depatuxizumab mafodotin, whose antibody (mAb 806) targets a unique tumor-specific epitope of EGFR and is currently being employed in several clinical trials in patients with glioblastoma or with EGFR-overexpressed solid tumors [90]. The gene discussed is EGFR; the disease is glioblastoma.